Diseases /
Chronic Myeloid Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. [1]
Chronic myeloid leukemias most frequently harbor alterations in ABL1, BCR, ASXL1, TET2, and RUNX1 [2].
BCR-ABL1 Fusion, BCR Fusion, ABL1-BCR Fusion, ABL1 Fusion, and ABL1 Mutation are the most common alterations in chronic myeloid leukemia [2].
Biomarker-Directed Therapies
Clinical Trials
Significant Genes in Chronic Myeloid Leukemia
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.